Spotlight On... Report says CMOs without U.S. facilities risk being left out of 'hot' market; Sweden acts against Svenska Bioforce; 6 pharma workers killed in India; and more...

A new report from CPhI of the U.S. market says that international API and drug manufacturers need to consider investing in U.S. manufacturing sites as drugmakers look to source products in the U.S. because of concerns over quality in some other countries. It says that "for contract manufacturing, the U.S. market is now as hot as it has been at any other time in the last 10 years, with a scramble occurring across international players to get a domestic manufacturing foothold in the market," especially in specialized areas such as biologics. Release

> An explosion of a bioreactor at an Indian pharmaceutical plant killed 6 workers. Story

> Dublin-based Sigmoid Pharma has acquired Freund Pharmatec, picking up its manufacturing facilities and labs in Tullamore, Ireland. Release

> Canada-based Nuvo Research has extended the end of an agreement it has for Dublin-based Horizon Pharma ($HZNP) to manufacture Nuvo's Pennsaid 2% for the U.S. market through Dec. 31, 2029. Release

> Baltimore rapper Davon Robeson, known as Day Day da Great, was convicted in Baltimore for his part in a 2010 robbery of a pharmaceutical delivery truck. Story

> Sweden has taken steps against drug producer Svenska Bioforce after finding 17 issues during an inspection of its sites. Access report here

> Transgene SA, which is developing immunotherapies, has sold a clinical supply manufacturing operation in Illkirch, France, to CMO ABL. Release

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)